ReviewInternational journal of molecular sciences2025
Mesenchymal Stem Cell Secretome for Cardiac Regeneration: Opportunity for Cell-Free Therapy.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free therapy is gaining increasing interest among researchers as an alternative to mesenchymal stem/stromal cell (MSC) therapy. Since the therapeutic effects of MSCs rely predominantly on their paracrine activity, the use of their secretome as a therapeutic agent in broadly defined regenerative medicine, including cardiac regeneration, appears to be a rational approach. In this review, we discuss recent studies that employed secretomes derived from various types of MSCs in cardiomyocyte regeneration following myocardial infarction (MI). Special attention is given to the protein components of the secretome, which may drive tissue repair, and methods of priming the MSC to achieve secretome composition tailored for heart regeneration. Finally, we summarize recent preclinical findings on the effects of MSC secretomes on cardiomyocyte regeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.